Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesOutcomes of patients with stage III non-small cell lung cancer treated with chemotherapy and radiation with and without surgery
Cancer, 06/26/09
Caglar HB et al. - In a study to identify the factors associated with improved outcome after treatment for stage III non-small cell lung cancer (NSCLC), it seems that stage at the time of treatment (stage IIIA vs stage IIIB) and use of surgery were the only factors associated with improved outcome.
Methods- A retrospective review of stage III NSCLC pts was done.
- Pts were followed for toxicity, local and distant failure, and overall survival (OS).
- Multivariate Cox logistic regression analysis was used to determine factors associated with treatment outcome.
- 144 pts received concurrent chemoradiation (CRT) for stage III NSCLC.
- 80 of 144 pts were men (56%), and median age was 61 yrs.
- 62 pts (43%) had stage IIIA NSCLC, and 82 pts (57%) had stage IIIB NSCLC.
- Radiotherapy (RT) was given concurrently with chemotherapy to all pts; 100 pts (69%) received CRT without surgery, and 44 pts (31%) received with neoadjuvant CRT followed by surgical resection.
- Median RT dose was 60 grays (Gy).
- Median follow-up was 15 mos, median potential follow-up was 37 mos, and median OS was 22 mos.
- 1-yr and 2-yr survival rates were 68% and 47%, respectively.
- Among the 44 pts who underwent resection, median survival was 61 mos, and 2-yr survival rate was 73%.
- On multivariate analysis, stage at the time of treatment (stage IIIA vs stage IIIB) and use of surgery were the only factors associated with improved outcome.
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Tumor necrosis factor inhibitors and lung disease: A paradox of efficacy and risk
Seminars in Arthritis and Rheumatism, 11/20/09
Sponsor
Article Search
Sponsor